To further evaluate the ability of eEF-2K knockdown to sensitize breast cancer cells to doxorubicin, we decided to assess whether eEF-2K knockdown sensitized MCF-7 cells that are resistant to doxorubicin (MCF-7/DoxR cells). Here, EEF2K is linked to breast cancer.